A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia

NCT ID: NCT04784442

Last Updated: 2024-05-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 188 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-24
• Study Completion Date: 2022-05-17

Brief Summary

The purpose of this study is to assess the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy and safety of ETC-1002(bempedoic acid) 60 mg, 120 mg and 180 mg versus placebo added to ongoing stable statin therapy or other lipid-modifying therapies in Japanese patients with hypercholesterolemia treated for 12 weeks.

Conditions

Hypercholesterolemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

ETC-1002 180mg

Group Type: EXPERIMENTAL

180mg of ETC-1002(bempedoic acid)

Intervention Type: DRUG

180mg, tablet, once daily, for 12 weeks

ETC-1002 120mg

Group Type: EXPERIMENTAL

120mg of ETC-1002(bempedoic acid)

Intervention Type: DRUG

120mg, tablet, once daily, for 12 weeks

ETC-1002 60mg

Group Type: EXPERIMENTAL

60mg of ETC-1002(bempedoic acid)

Intervention Type: DRUG

60mg, tablet, once daily, for 12 weeks

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

placebo, tablet, once daily, for 12 weeks

Interventions

180mg of ETC-1002(bempedoic acid)

180mg, tablet, once daily, for 12 weeks

Intervention Type: DRUG

120mg of ETC-1002(bempedoic acid)

120mg, tablet, once daily, for 12 weeks

Intervention Type: DRUG

60mg of ETC-1002(bempedoic acid)

60mg, tablet, once daily, for 12 weeks

Intervention Type: DRUG

Placebo

placebo, tablet, once daily, for 12 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients who have obtained informed consent to all of the observation/examination/evaluation items specified in the protocol
• Patients must be on stable statin therapy defined as atorvastatin, pitavastatin, rosuvastatin, pravastatin, simvastatin, or fluvastatin daily[and other lipid-modifying therapies(LMTs) if needed] at least 4 weeks(6 weeks for fibrates) prior to screening and above LDL-C control target. Or Patients for statin intolerant must be on stable LMT(s) at least 4 weeks prior to screening and above LDL-C control target. Statin intolerance defined as an inability to tolerate 1 or more statins due to an adverse safety effect that started or increased during statin therapy and resolved or improved when statin therapy was discontinued or decreased. Patients on the lowest or under the dosage of the approved dose of statin or unable to tolerate any statin at any dose were eligible. Patients could continue taking the lowest or under the dosage of the approved dose of statin therapy or taking other LMTs throughout the study provided that it was stable and well tolerated.
• Fasting mean TG level < 400 mg/dL from measurements at screening

Exclusion Criteria

• Women who are pregnant or breastfeeding or who have a positive pregnancy test (urine) result at screening or baseline visits
• Sexually active male subjects or sexually active female subjects of childbearing potential who do not agree to practice 2 different methods of birth control or to remain abstinent during the trial and for 30 days after final IMP administration test (urine) result at screening or baseline visits
• Patients with homozygous familial hypercholesterolemia (HoFH)
• Patients with a history or current symptoms of any of the following clinically significant cardiovascular diseases within 3 months prior to screening or before baseline visit

• Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, stroke, transient ischemic attack, symptomatic carotid artery stenosis, symptomatic peripheral arterial disease, or decompensated heart failure
• Abdominal aortic aneurysm
• Unexplained syncope or long-QT syndrome, family history of long-QT syndrome, or risk factors for Torsade de Pointes, such as persistent hypokalemia or second- or third-degree atrioventricular block (except when controlled by medication, etc)
• Uncontrolled hypertension, defined as follows:

• Sitting systolic blood pressure after resting 5 minutes of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg at screening
• Patients with uncontrolled and serious hematologic or coagulation disorders or with Hgb of <10.0 g/dL at screening
• Patients with type 1 diabetes or uncontrolled type 2 diabetes with hemoglobin A1c (HbA1c) of ≥9% at screening
• Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of >1.5 × ULN at screening
• Patients with liver disease or dysfunction, including:

• Positive serology for hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies at screening
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥3 × ULN and/or total bilirubin of ≥2 × ULN
• Patients with creatine kinase (CK) elevation( >3 × ULN) at screening
• Patients with renal dysfunction or nephritic syndrome or a history of nephritis and with estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73m2 at screening

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 74 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Takehisa Matsumaru

Role: STUDY_DIRECTOR

Otsuka Pharmaceutical Co., Ltd.

Locations

Tokyo-Eki Center-Building Clinic

Chuo-ku,Tokyo, , Japan

Countries

Japan

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

jRCT2031200445

Identifier Type: OTHER

Identifier Source: secondary_id

346-102-00001

Identifier Type: -

Identifier Source: org_study_id